Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate

Virology

Volumn 347, Issue 2, 2006, Pages 405-409

  Kolli, Madhavi ^a   Lastere, Stephane ^b   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BICHAT HOSPITAL   (France)

Author keywords

Co evolution; D30N; Drug resistance; HIV 1; p1 p6; Protease

Indexed keywords

NELFINAVIR; PROTEINASE;

AMINO ACID SEQUENCE; ARTICLE; COEVOLUTION; COMPARATIVE STUDY; CORRELATION ANALYSIS; ENZYME ANALYSIS; ENZYME SUBSTRATE; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; PRIORITY JOURNAL; VALIDATION PROCESS;

DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENE PRODUCTS, GAG; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; NELFINAVIR; SUBSTRATE SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33646043172     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2005.11.049     Document Type: Article

References (14)

1. Bally F., Martinez R., Peters S., Sudre P., and Telenti A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease. AIDS Res. Hum. Retroviruses 16 13 (2000) 1209-1213
2. Doyon L., Croteau G., Thibeault D., Poulin F., Pilote L., and Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70 6 (1996) 3763-3769
3. Feher A., Weber I.T., Bagossi P., Baross P., Mahalingam B., Louis J.M., Copeland T.D., Yorshin I.Y., Arrison R.W., and Tozser J. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. J. Biochem. 269 (2002) 4114-4120
4. Ferrin T.E., Huang C.C., Jarvis L.E., and Langridge R. The MIDAS display system. J. Mol. Graphics 6 (1988) 13-27
5. Hoffman N., Schiffer C.A., and Swanstrom R. Covariation of amino acid positions in HIV-1 protease. Virology 314 (2003) 536-548
6. Kaldor S.W., Kalish V.J., Davies J.n., Shetty B.V., Fritz J.E., Appelt K., Burgess J.A., Campanale K.M., Chirgadze N.Y., Clawson D.K., Dressman B.A., Hatch S.D., Khalil D.A., Kosa M.B., Lubbehusen P.P., Muesing M.A., Patick A.K., Reich S.H., Su K.S., and Tatlock J.H. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40 24 (1997) 3979-3985
7. Mammano F., Petit C., and Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 72 9 (1998) 7632-7637
8. Meynard J.L., Vray M., Morand-Joubert L., Race E., Descamps D., Peytavin G., Matheron S., Lamotte C., Guiramand S., Costagliola D., Brun-Vezinet F., Clavel F., Girard P.M., and Group N.T. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16 5 (2002) 727-736
9. Pai V.B., and Nahata M.C.A.P. Nelfinavir mesylate: a protease inhibitor. Ann. Pharmacother. 33 3 (1999) 325-339
10. Patick A., Duran M., Cao Y., Shugarts D., Keller M., Mazabel E., Knowles M., Chapman S., Kuritzkes D., and Markowitz M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42 10 (1998) 2637-2644
11. Prabu-Jeyabalan M., Nalivaika E.A., and Schiffer C.A. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10 3 (2002) 369-381
12. Prabu-Jeyabalan M., King N.M., Nalivaika E., and Schiffer C.A. Co-evolution of the Nucleocapsid-p1 cleavage site with the V82A mutation in HIV-1 protease preserves substrate recognition. J. Virol. 78 22 (2004) 12446-12454
13. Wlodawer A., and Erickson J.W. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62 (1993) 543-585
14. Wu T.D., Schiffer C.A., Gonzales M.J., Taylor J., Kantor R., Chou S., Israelski D., Zolopa A.R., Fessel W.J., and Shafer R.W. Mutation patterns and structural correlates in HIV-1 protease following varying degrees of protease inhibitor treatment. J. Virol. 77 (2003) 4836-4847